Abstract:Interleukin (IL)-22 is a member of the IL-10 family and produced by many immune cells 1, 2. It plays an important role in the pathogenesis of psoriasis, a skin disease characterized by epidermal hyperplasia associated with altered keratinocyte differentiation 3. IL-22 alters multiple biological behaviours of keratinocytes, including proliferation, differentiation, migration and cytokine production. Heparin-binding epidermal growth factor-like growth factor (HB-EGF), a member of the EGF family, plays a critical role in keratinocyte biology. HB-EGF shows the ability to promote keratinocyte proliferation and epidermal hyperplasia 4. IL-22 has been reported to stimulate HB-EGF production in keratinocytes 5. What are the effects of IL-22 on the proliferation and HB-EGF expression in HaCaT keratinocytes? Which signalling pathways are involved in the modulation of HB-EGF by IL-22? A detailed description of the materials and methods is provided in the Supplementary Materials available online. IL-22 at different concentrations ranging from 12.5 to 100 μg/l 1 significantly (P < 0.05) stimulated HaCaT cell proliferation, compared to untreated cells (Fig. 1a). As IL-22 at 50 and 100 μg/l induced a similar maximal proliferation response, the concentration of 50 μg/l was used in the following experiments, if not stated otherwise. To confirm the proliferation-inducing role of IL-22, we knocked down its expression using small interfering RNA (siRNA) technology. As shown in Fig. 1b, downregulation of IL-22 significantly inhibited the proliferation of HaCaT cells, compared to cells transfected with negative control siRNA. We also examined the effect of IL-22 on the expression and secretion of HB-EGF in HaCaT cells. Exposure to IL-22 for 24 h caused a significant and concentration-dependent increase in HB-EGF mRNA abundance, compared to untreated cells (Fig. 1c). The induction of HB-EGF expression by IL-22 was further confirmed at the protein level by Western blot (Fig. 1d) and enzyme-linked immunosorbent assay (ELISA) analysis (Fig. 1e). Next, we checked the involvement of STAT3 and ERK1/2 signalling in the effects of IL-22 in HaCaT cells. Western blot analysis showed that IL-22 promoted the phosphorylation of JAK2, STAT3 and ERK1/2 in HaCaT cells, compared to untreated control (Fig. 2a). The total levels of JAK2, STAT3 and ERK1/2 protein remained unchanged. Notably, pre-incubation of HaCaT cells with AG490 (an inhibitor of JAK2/STAT3 signalling) or PD-98059 (an inhibitor of ERK1/2) significantly impaired the induction of HB-EGF expression by IL-22 (Fig. 2b–d). IL-22 exerts its biological activity through IL-22 receptor, which is expressed on human keratinocytes 5. This cytokine has been found to induce the proliferation of keratinocytes 6. Consistently, our data demonstrated that IL-22 treatment significantly accelerated the proliferation of HaCaT cells. Moreover, siRNA-mediated depletion of IL-22 impeded HaCaT cell proliferation. These results indicate that IL-22 is required for the proliferation of keratinocytes. Tohyama et al. 5 reported that IL-22 facilitated the production of HB-EGF in cultured keratinocytes. Consistently, we found that IL-22 treatment caused a significant increase in both the HB-EGF mRNA and protein levels in HaCaT cells. Moreover, the production of soluble HB-EGF was significantly enhanced by IL-22 treatment. HB-EGF shows the ability to stimulate keratinocyte proliferation 4. Thus, HB-EGF may mediate the proliferation-inducing effect of IL-22 in epidermal keratinocytes. However, further studies are needed to validate the induction of HB-EGF by IL-22 in normal human keratinocytes. Mechanistically, activation of both JAK2/STAT3 and ERK1/2 signalling pathways contributes to the induction of HB-EGF by IL-22 in keratinocytes. This conclusion is supported by the findings that pretreatment of HaCaT cells with specific inhibitors of STAT3 or ERK1/2 signalling significantly reversed the upregulation of HB-EGF by IL-22. The modulation of STAT3 and ERK1/2 signalling pathways by IL-22 has also been described in other biological settings. For instance, Fukui et al. 7 demonstrated that IL-22 can facilitate gastric cancer cell invasion through activation of STAT3 and ERK signalling. Taken together, IL-22 promotes HaCaT cell proliferation, which is associated with upregulation of HB-EGF via activation of both STAT3 and ERK1/2 pathways. The IL-22/HB-EGF axis may represent a promising therapeutic target for psoriasis and other cutaneous diseases characterized by keratinocyte hyperproliferation. This work was supported by the National Natural Science Foundation of China (No.81201231, 81371732). Suju Luo, Quanzhong Liu, Yan Zheng and Haiyang Ni designed the study. Xinxin Liu, Wenjuan Xu and Yan Li performed the research and analysed the data. Suju Luo and Yan Zheng wrote the article. The authors have declared no conflicting interests. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Interleukin-22 Inhibits Tazarotene-Induced Gene 3 Expression in HaCaT Cells Via MAPK-ERK1/2 and JAK2/STAT3 Signaling.

Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis

Effects of Interleukin-22 on the Expression of Tazarotene-Induced Gene 3 in HaCaT Cells

Elevated IL-22 in psoriasis plays an anti-apoptotic role in keratinocytes through mediating Bcl-xL/Bax

Limited Presence of IL-22 Binding Protein, a Natural IL-22 Inhibitor, Strengthens Psoriatic Skin Inflammation

IL23R mutations associated with decreased risk of psoriasis lead to the differential expression of genes implicated in the disease

OAS1, OAS2, and OAS3 Contribute to Epidermal Keratinocyte Proliferation by Regulating Cell Cycle and Augmenting IFN-1‒Induced Jak1‒Signal Transducer and Activator of Transcription 1 Phosphorylation in Psoriasis.

SAT0459 Low Dose IL-2 Restores Imbalance Between TH17 and Regulatory T Cells in Patients with Psoriatic Arthritis

miR-22 promotes immunosuppression via activating JAK/STAT3 signaling in cutaneous squamous cell carcinoma

Luteolin-7-glucoside inhibits IL-22/STAT3 pathway, reducing proliferation, acanthosis, and inflammation in keratinocytes and in mouse psoriatic model

Interleukin-22 and Its Correlation with Disease Activity in Plaque Psoriasis

IL-6 Up-Regulates Expression of LIM-Domain Only Protein 4 in Psoriatic Keratinocytes through Activation of the MEK/ERK/NF-κB Pathway

Interleukin‐17A suppresses granular layer formation in a 3‐D human epidermis model through regulation of terminal differentiation genes

Interleukin‐22 Upregulates HB‐EGF Expression in HaCaT Cells Via JAK2/STAT3 and ERK1/2 Signalling

Weighted gene coexpression network and experimental analyses identify lncRNA SPRR2C as a regulator of the IL-22-stimulated HaCaT cell phenotype through the miR-330/STAT1/S100A7 axis

Interleukin-22: A Likely Target for Treatment of Autoimmune Diseases

Downregulation of circ_0024028 inhibits IL-22-induced keratinocyte proliferation and migration by miR-486-3p/AKT3 axis

IL-23 induces CLEC5A+ IL-17A+ neutrophils and elicit skin inflammation associated with psoriatic arthritis

LncRNA MALAT-1 Regulates the Growth of Interleukin-22-stimulated Keratinocytes Via the Mir-330-5p/s100a7 Axis

The Role of IL-17 Cytokines in Psoriasis